Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Radiolabeled antibody targeting of the HER-2/neu oncoprotein.

De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O.

Cancer Res. 1992 Apr 1;52(7):1916-23.

PMID:
1348016
[PubMed - indexed for MEDLINE]
Free Article
2.

Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE.

Bioconjug Chem. 2000 May-Jun;11(3):327-34.

PMID:
10821648
[PubMed - indexed for MEDLINE]
3.

Radioiodinated antibody targeting of the HER-2/neu oncoprotein.

Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, Bast RC Jr, Zalutsky MR.

Nucl Med Biol. 1997 Jul;24(5):451-9.

PMID:
9290082
[PubMed - indexed for MEDLINE]
4.

Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.

Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M, Yarden Y.

Cancer Res. 1992 May 1;52(9):2580-9.

PMID:
1373672
[PubMed - indexed for MEDLINE]
Free Article
5.

Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.

Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A, et al.

J Clin Immunol. 1991 May;11(3):117-27. Review.

PMID:
1679763
[PubMed - indexed for MEDLINE]
6.

Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA.

J Nucl Med. 1997 Dec;38(12):1944-50.

PMID:
9430475
[PubMed - indexed for MEDLINE]
Free Article
8.

Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.

Drebin JA, Link VC, Greene MI.

Oncogene. 1988 Apr;2(4):387-94.

PMID:
2896329
[PubMed - indexed for MEDLINE]
9.

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.

Oncogene. 1998 Oct 29;17(17):2235-49.

PMID:
9811454
[PubMed - indexed for MEDLINE]
Free Article
10.

Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC Jr.

Int J Cancer. 1993 Feb 1;53(3):401-8.

PMID:
7679090
[PubMed - indexed for MEDLINE]
11.

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.

J Nucl Med. 2006 Jul;47(7):1127-35.

PMID:
16818947
[PubMed - indexed for MEDLINE]
Free Article
12.

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.

Oncogene. 1994 Jul;9(7):1829-38.

PMID:
7911565
[PubMed - indexed for MEDLINE]
13.

Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.

Sato N, Saga T, Sakahara H, Yao Z, Nakamoto Y, Zhang M, Kuroki M, Matsuoka Y, Iida Y, Konishi J.

J Nucl Med. 1999 Apr;40(4):685-92.

PMID:
10210230
[PubMed - indexed for MEDLINE]
Free Article
14.

An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.

Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE.

Cancer Res. 1991 May 15;51(10):2593-8.

PMID:
1673637
[PubMed - indexed for MEDLINE]
Free Article
15.

Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.

Riccobene TA, Miceli RC, Lincoln C, Knight Y, Meadows J, Stabin MG, Sung C.

J Nucl Med. 2003 Mar;44(3):422-33.

PMID:
12621010
[PubMed - indexed for MEDLINE]
Free Article
16.

Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells.

Marth C, Cronauer MV, Doppler W, Ofner D, Ullrich A, Daxenbichler G.

Int J Cancer. 1992 Jan 2;50(1):64-8.

PMID:
1370227
[PubMed - indexed for MEDLINE]
17.

Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC Jr.

Int J Cancer. 1999 Aug 12;82(4):525-31.

PMID:
10404066
[PubMed - indexed for MEDLINE]
18.

Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.

Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, Blumenthal RD, Goldenberg DM, Becker W.

Int J Cancer. 1998 May 29;76(5):738-48.

PMID:
9610734
[PubMed - indexed for MEDLINE]
19.

A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.

Cancer Res. 1993 Jan 1;53(1):94-100.

PMID:
8093231
[PubMed - indexed for MEDLINE]
Free Article
20.

186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.

Kotts CE, Su FM, Leddy C, Dodd T, Scates S, Shalaby MR, Wirth CM, Giltinan D, Schroff RW, Fritzberg AR, Shepard HM, Slamon DJ, Hutchins BM.

Cancer Biother Radiopharm. 1996 Apr;11(2):133-44.

PMID:
10851530
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk